The Pharmacokinetic Profile of a New Gastroresistant Capsule Preparation of Eicosapentaenoic Acid as the Free Fatty Acid

Table 1

Subject characteristics.

Characteristic°	Crohn’s disease; ( = 10)	Ulcerative colitis; ( = 10)	Healthy volunteers; ( = 15)
Age (years) mean ± SD	39 ± 11	34 ± 10	28 ± 8
Male (%)	6 (60)	4 (40)	5 (33.3)
Current smoker (%)	3 (30)	1 (10)	4 (26.6)
Duration of disease (months)
Mean ± SD	68 ± 32	65 ± 28	—
Previous intestinal resection (%)	2 (20)	0 (0)	0 (0)
CDAI^*
Median (range)	82 (38–102)	/	/
SCCAI^*
Median (range)	/	0 (0)	/
Site of involvement (%)
Ileum	4 (40)	/	/
Ileum and colon	3 (30)	/	/
Colon	3 (30)	/	/
Pancolitis	/	3 (30)	/
Left-sided colitis	/	7 (70)	/
Ongoing drug therapy (%)
Immunosuppressive agents	4 (40)	2 (20)	/
Mesalamine	6 (60)	8 (80)

CDAI: Crohn’s disease activity index; SCCAI: simple clinical colitis activity index; = ns.